Phase II Trial of Sorafenib in Patients With Myelodysplastic Syndrome.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 20 Dec 2013 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 01 Aug 2011 Planned end date changed from Dec 2014 to Dec 2012 as reported by ClinicalTrials.gov.
- 01 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.